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BREAST CANCER IN YOUNG WOMEN: 
PATHOLOGIC AND IMMUNOHISTOCHEMICAL 
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SUMMARY – A young woman with breast cancer is considered to be a woman younger than 40. 
According to the literature, breast cancer in the population of young women usually is of a higher 
histologic grade, unfavorable hormonal status, and overall higher mortality rate when compared with 
breast cancer occurring in older population. We compared pathologic and immunohistochemical fea-
tures of breast carcinoma in women under 40 years of age with the respective features in women over 
60 years of age. Th e following parameters were observed in these two groups: tumor size, lymph node 
status, histologic grade, hormonal receptor status, Ki-67 prognostic index, Her2/neu status, and histo-
logic type of the tumor. Early onset breast carcinoma was found to have a higher frequency of tumor 
grade 3 (29% vs. 17%) and estrogen receptor negativity (45% vs. 23%). In the group of young women, 
breast carcinoma was mostly multicentric (23% vs. 5%), triple-negative (32% vs. 10%), and was found 
to have higher proliferation index Ki-67 (25% vs. 10%). Our results confi rmed diff erences between the 
young and older groups of patients. In the group of young women, we found predominantly unfavor-
able prognostic parameters of the disease.
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Introduction
Breast cancer is a global public health issue. It is the 
most common malignancy in women and the most 
common mortality factor in the population of women. 
Due to the expansion of novel therapeutic options, 
from surgical and oncologic perspective, and with 
greater potential of recovery, breast cancer is one of the 
most widely researched malignancies in the past twen-
ty years. Young women with breast cancer are consid-
ered to be those under 40 years of age1,2. In this popu-
lation, breast carcinoma is the most common malig-
nant disease and has the greatest mortality, although 
the rate of the total number of breast cancer cases is 
6%3. Numerous clinical studies have confi rmed that 
breast cancer in young women has a higher histologic 
grade, unfavorable hormonal status, and overall higher 
death rate compared to the older population of wom-
en4-6. Th is leads to a conclusion that treatment ap-
proach should be radical. Current treatment approach 
to breast carcinoma is multimodal. Surgical procedure 
must ensure removal of malignancy with an exact stag-
ing of axillary lymph nodes. Surgical treatment is es-
sential in therapeutic approach to breast carcinoma, 
however, several main issues such as disease recurrence 
and distant metastases persist. Th erefore, radiotherapy 
and chemotherapy (adjuvant or neoadjuvant) are in-
herent part in the treatment of breast carcinoma7-9. Th e 
aim of this study was to compare the characteristics of 
breast cancer in a group of young women with a group 
of postmenopausal women and confi rm the higher 
malignant potential of cancer in the population of 
young women.
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Materials and Methods
In this retrospective study, data were collected from 
medical charts of patients that had undergone surgical 
treatment between 2002 and 2010 at the Department 
of Surgery, Osijek University Hospital Centre in 
Osijek, Croatia. Patients were divided into two groups. 
Th e fi rst group consisted of young women (YW) less 
than 40 years of age. Th e second group encompassed 
postmenopausal women (PMW) over 60 years of age 
and according to our data with no menstrual cycle. 
Th ese two groups were compared according to the fol-
lowing parameters: tumor size, lymph node status, his-
tologic grade, hormonal receptor status, Ki-67 prog-
nostic index, Her2/neu status, and histologic type of 
tumor. All patients included in the study had complete 
documentation. Th ose with incomplete documenta-
tion and data were excluded from the study. All study 
patients had tumor stage 1-3. Patients with positive 
distant metastasis (M) at the time of diagnosis were 
not included in the study.
We collected data on 166 patients, 79 YW (47.6%), 
median age 37 (range, 33-39) years, and 87 PMW 
(52.4%), median age 69 (range, 65-73) years.
Breast tissue was fi xed, paraffi  n embedded and cut 
into 5-μm sections. Th en it was stained and observed 
under a microscope. Hormonal status, Her2/neu status 
and Ki 67 were determined by immunochemical stain-
ing. Among patients with Her2/neu 2+, the FISH 
method was performed to determine whether the pa-
tient was Her2/neu positive or negative.
We used the TNM classifi cation from the Ameri-
can Joint Committee on Cancer Staging System for 
Breast Cancer from 2010. Histologic grading of breast 
carcinoma was performed by Elston and Ellis method.
Statistical analysis was performed with SPSS 13.0 
(Chicago, IL). On comparison of patient groups, Fish-
er exact test, χ2-test and Mann-Whitney U test were 
used. Th e level of statistical signifi cance was set at 
p<0.05.
Results
Data on 166 patients were collected, 79 (47.6%) in 
the YW group, median age 37 (range, 33-39) years, 
and 87 (52.4%) in the PMW group, median age 69 
(range, 65-73) years (Table 1). Th ere was no signifi cant 
diff erence in operated side between YW (right 40%-
50.4%; left 39%-49.6%) and PMW (right 44%-50.4%; 
left 43%-49.6%).
Invasive ductal carcinoma was the most frequent 
histologic type of tumor in both groups. In the YW 
group, 56 (70.9%) tumors were histologically invasive 
ductal carcinoma, whereas in the PMW group 52 
(59.8%) patients had this type of tumor. Invasive lobu-
lar carcinoma was found to be the second most com-
mon type in both patient groups in our sample.
Regarding the size of tumor, there were no statisti-
cally signifi cant diff erences between patient groups in 
T1-T3 sizes. Th e T4 tumor size (any size with the skin 
or chest wall spread) was recorded in nine (10.3%) 
PMW group patients and three (3.8%) YW group pa-
tients (χ2-test, p=0.036). Th ere were no statistically 
 signifi cant between-group diff erences in lymph node 
status and N1-N3 parameters.
Negative estrogen receptor status was found in 36 
(45.6%) YW and 20 (23%) PMW patients (Fisher 
 exact test, p=0.003). Positive estrogen receptor status 
was found to be more positive in PMW group as com-
pared with YW group: 67 (77%) versus 43 (54.4%); 
however, these diff erences were not statistically signifi -
cant (Table 1).
Negative progesterone receptor status had 35 
(44.3%) WY patients and 33 (37%) PMW patients. 
Positive progesterone receptor status was found in 44 
(55.7%) YW patients and 54 (62.1%) PMW patients. 
Diff erences in progesterone receptor status between 
the groups were not statistically signifi cant (Fisher 
 exact test, p=0.433).
Th e Her2/neu receptor status was also investigated 
in both patient groups. As shown in Table 1, there 
were no statistically signifi cant between-group diff er-
ences in either positive or negative Her2/neu status.
Th e rate of triple-negative breast carcinoma (ne-
gative estrogen and progesterone receptors, negative 
Her2/neu) was found to be signifi cantly higher in 
YW patients as compared with PMW patients: 25 
(32.1%) versus nine (10.3%) (Fisher exact test, p=0.001) 
(Table 1).
Th e Ki-67 proliferation index was signifi cantly 
lower in PMW group (median 10.4%; interquartile 
range 5%-25%) as compared with YW group (median 
25%; interquartile range 11% to up to 48%) (Mann-
Whitney U test, p<0.001).
Modifi ed radical mastectomy with axillary lymph 
node dissection was the preferred operation type in 
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118 (71.1%) patients, while the breast conserving 
surgery with axillary lymph node dissection was pre-
ferred in 48 (28.9%) patients, equally in both age 
groups.
We found a signifi cantly higher incidence of mul-
ticentric tumor in YW patients (n=18; 23.15%) as 
compared with PMW patients (n=5; 5.7%) (Fisher 
exact test, p=0.001) (Table 1).




Aff ected side, n (%)
right 40 (50.6) 44 (50.6) 84 (50.6)
>0.950†
left 39 (49.4) 43 (49.4) 82 (49.4)
Histologic type, n (%)
ductal invasive 56 (70.9) 52 (59.8) 108 (65.1)
0.244*lobular invasive 11 (13.9) 15 (17.2) 26 (15.7)
other 12 (15.2) 20 (23) 32 (19.3)
Tumor size (T), n (%)
T1 ≤2 cm 39 (49.4) 27 (31) 66 (39.8)
0.036*
T2 >2 cm ≤5cm 30 (38) 46 (52.9) 76 (45.8)
T3 >5 cm 7 (8.9) 5 (5.7) 12 (7.2)
T4 any size with skin or chest wall spread 3 (3.8) 9 (10.3) 12 (7.2)
Positive lymph nodes, n (%) 49 (62) 45 (51.7) 94 (56.6) 0.211*
Lymph node status, n (%)
1-3 lymph nodes 30 (61.2) 17 (37.8) 47 (50)
0.057*4-9 lymph nodes 13 (26.5) 16 (35.6) 29 (30.9)
≥10 lymph nodes 6 (12.2) 12 (26.7) 18 (19.1)
Estrogen status, n (%)
negative 36 (45.6) 20 (23) 56 (33.7)
0.003†
positive 43 (54.4) 67 (77) 110 (66.3)
Progesterone status, n (%)
negative 35 (44.3) 33 (37.9) 68 (41)
0.433†
positive 44 (55.7) 54 (62.1) 98 (59)
HER-2/neu status, n (%)
negative 60 (75.9) 69 (79.3) 129 (77.7)
0.709†
positive 19 (24.1) 18 (20.7) 37 (22.3)









Type of surgical procedure, n (%)
mastectomy sec Madden 52 (65.8) 66 (75.9) 118 (71.1)
0.173†
breast conserving resection 27 (34.2) 21 (24.1) 48 (28.9)
Multicentric tumor position, n (%) 18 (23.1) 5 (5.7) 23 (13.9) 0.001†
Histologic grade, n (%)
I 13 (16.5) 33 (39.3) 46 (28.2)
0.004*II 43 (54.4) 36 (42.9) 79 (48.5)
III 23 (29.1) 15 (17.9) 38 (23.3)
*χ2-test; †Fisher exact test; ‡Mann Whitney U test
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Th e majority of patients, 79 (48.5%) of them, had 
histologic grade 2. Grade 3 was found in 38 (23.3%) 
patients and the distribution was signifi cantly higher 
in the YW patient group (Fisher exact test, p=0.004) 
(Table 1).
Discussion
In developed countries, 5%-7% of all patients with 
breast cancer are younger than 40 years of age3. In 
China, young patients with breast cancer account for 
5%-13% of all breast cancer cases10. Breast cancer that 
occurs in younger age is considered to be diff erent than 
the one in older patients. Th ese carcinomas tend to 
have more aggressive biologic nature, higher tumor 
grade, and higher proliferation fraction with more vas-
cular invasion than the same malignancies found in 
older women4. Young patients with breast cancer are 
faced with numerous psychological challenges, with a 
greater incidence of radical mastectomy, premature 
menopause, and infertility11. In young patients, the 
disease has worse prognosis in terms of overall survival 
and disease recurrence12. Various studies identifi ed 
young age as an independent factor of poor disease 
prognosis13,14.
In our sample, we found no diff erence in cancer 
laterality according to patient age (YW and PMW 
groups). In a study on 687 patients, there was no dif-
ference in breast cancer laterality in general and when 
divided to age subgroups15. Invasive ductal carcinoma 
was the most frequent histologic type of tumor. Th e 
second most common type was invasive lobular carci-
noma. Diff erent studies confi rmed invasive ductal car-
cinoma as one of the most frequent cancers in general 
and among women under 40 years of age16,17. A study 
conducted at the Mount Sinai Medical Center in New 
York found that younger patients had larger tumors 
with more nodal involvement6. However, we found no 
diff erence in these parameters, which is consistent 
with the fi ndings reported by Colleoni et al.18.
We found a signifi cantly higher negative estrogen 
receptor status in the YW patient group, but there 
were no diff erences in estrogen positive or progester-
one status. Histology grade 3 was signifi cantly more 
frequent in the group of young patients. Gnerlich et al. 
found that young women had tumors with negative 
estrogen and progesterone receptor status but accom-
panied with higher histologic grade19. Th ese character-
istics are usually associated with more aggressive tu-
mors, poorer prognosis, and linked with Her2/neu 
overexpression.
Her2/neu overexpression has been reported in tu-
mors developing at a younger age and considered to be 
part of aggressive immunophenotype in breast cancer, 
especially with lymph node metastases20. On the other 
hand, Anders et al. found that Her2/neu status did not 
prove to be an independent factor of poor prognosis in 
young patients with cancer21. We found no diff erence 
in Her2/neu overexpression between patient groups in 
our sample. However, we did fi nd a signifi cantly high-
er proportion of triple-negative tumor (32%) in the 
YW group. Triple-negative tumors were overrepre-
sented among young women with breast cancer with a 
rate of 25%22. Th ese carcinomas, particularly in young-
er women, are supposed to be associated with BRCA 1 
germline mutations and represent the most aggressive 
phenotype that is linked to poor prognosis23.
Many studies have suggested that Ki-67 is a pre-
dictive factor of the disease outcome in hormone posi-
tive tumors24. Munzone et al. demonstrated that Ki-67 
might predict response to chemotherapeutic treatment 
and was associated with disease prognosis in hormone 
negative patient groups25. In our sample, Ki-67 was 
found to be 25%, which is a high value pointing to 
poor prognosis of the disease in our YW group. In our 
YW group, 23% of all tumors had the multicentric 
 position as the fi nal pathologic fi nding. Multicentric 
tumors have been recognized as highly signifi cant pre-
dictors of reduced survival, increased local relapse, and 
distant metastases26. Th e presence of multicentric tu-
mor could be the reason for choosing the radical mas-
tectomy approach. However, with adjuvant chemora-
diotherapy, there is no diff erence in overall survival 
and disease-free survival between mastectomy and 
breast-sparing resection27.
Conclusion
Even though breast carcinoma in young women 
has a relatively small proportion (6%), it does not re-
duce its signifi cance and impact on public health. Th is 
research ascertained that breast carcinoma in young 
women (<40 years of age) is diff erent from breast car-
cinoma occurring in older women (>60 years of age). 
Th e main diff erences are negative estrogen receptor 
status, multicentric position, higher histologic grade, 
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triple-negative tumors, and higher Ki-67 index. Th ese 
features have been found to be the key attributes for 
aggressive disease course with increased probability of 
poor overall survival and disease-free survival.
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Sažetak
RAK DOJKE U MLADIH ŽENA: PATOLOŠKA I IMUNOHISTOKEMIJSKA OBILJEŽJA
I. Erić, A. Petek Erić, J. Kristek, I. Koprivčić i M. Babić
Mladom ženom s rakom dojke smatra se žena mlađa od 40 godina. Prema literaturi rak dojke u populaciji mladih žena 
ima obično viši histološki stupanj i nepovoljan hormonski status. Puno je veći postotak smrtnosti u mladoj populaciji nego 
kada se karcinom javlja u starijoj životnoj dobi. Usporedili smo patološka i imunohistokemijska obilježja karcinoma dojke 
kod žena ispod 40 godina s odgovarajućim obilježjima među ženama iznad 60 godina. Sljedeći parametri su promatrani kod 
ove dvije skupine: veličina tumora, stanje limfnih čvorova, histološki gradus, status hormonskih receptora, prognostički 
 indeks Ki-67, status Her2/neu i histološki tip tumora. Za karcinom dojke kod mladih žena utvrđeno je da ima veću učestalost 
tumora histološkog gradusa 3 (29% prema 17%) i negativnog statusa estrogenskih receptora (45% prema 23%). U skupini 
mladih žena rak dojke je uglavnom multicentričan (23% prema 5%), trostruko negativan (32% prema 10%) i ustanovljeno je 
da ima veći proliferacijski indeks Ki-67 (25% prema 10%). Naši rezultati potvrđuju razlike između mlade i starije skupine 
bolesnica. U skupini mladih žena utvrđeni su pretežito nepovoljni prognostički parametri bolesti.
Ključne riječi: Dojka, tumori; Ženska osoba; Limfni čvorovi; Hrvatska
